Mesoblast Limited (AU:MSB) has released an update. Mesoblast Limited announced that all resolutions at their recent Annual General Meeting were passed successfully, reflecting strong shareholder support. The poll results showed
Mesoblast Limited (AU:MSB) has released an update. Mesoblast Limited announced that all resolutions at their recent Annual General Meeting were passed successfully, reflecting strong shareholder support. The poll results showed
Mesoblast Limited (AU:MSB) has released an update. Mesoblast Limited has announced the departure of director Joseph Swedish, effective November 15, 2024. Swedish holds 1,327,077 options and 45,942 American Depositary Shares,
Mesoblast Limited (AU:MSB) has released an update. Mesoblast Limited, a leader in allogeneic cellular medicines for inflammatory diseases, discussed its forward-looking business strategies and financial expectations during its 2024 Annual
Mesoblast Limited (AU:MSB) has released an update. Mesoblast Limited is making strides in the development and potential commercialization of its cellular medicines, focusing on treatments for inflammatory conditions and heart
Mesoblast Limited (AU:MSB) has released an update. Mesoblast Limited has announced the issuance of 2 million unquoted warrants, following a previously declared transaction. These securities are not intended to be